The Ben Towne Center’s mission is to translate scientific discoveries into innovative therapies that cure childhood cancer with minimal side effects and improve survivors’ quality of life.
We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.
Our clinical trials are helping children with acute lymphoblastic leukemia achieve complete remission.
We use an innovative approach to carry therapies from the lab to the bedside, making them safer and more effective along the way.
Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.
You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.
Our researchers have started the first round of clinical trials exploring a potential cure.
Help us answer questions about childhood health and illness, and help other children in the future. Learn more.
Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.
Please visit Seattle Children’s careers page to learn about current openings.
For information about potential opportunities in the Ben Towne Center, email us.
Immunotherapy trial for relapsed leukemia shows 93% remission rate 6.2.16 – Seattle Children’s Press Release Thirty-nine of 42 pediatric patients with acute lymphoblastic leukemia achieved complete remission in a Phase 1 clinical trial at Seattle Children’s. The trial uses genetically reprogrammed T cells to find and kill leukemia cells. Patients in the trial had less than a 20% chance of survival with current treatments.
Seattle Children’s and Juno Therapeutics accelerate immunotherapy trials for brain cancers 5.25.16 – Seattle Children’s Press Release Seattle Children’s signed a letter of intent with Juno Therapeutics Inc. to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors, known as gliomas.
Immunotherapy research gives Jude a new chance at life 12.21.15 – Seattle Children’s Press Release After Jude Anderson’s leukemia relapsed twice, the 3-year-old was out of treatment options. Then Seattle Children’s immunotherapy clinical trial helped him achieve remission, thanks to financial support from people across the country who make these clinical trials possible.
Email the BTCCCR
1100 Olive Way, Suite 100
Seattle, WA 98101
PO Box 5371
Seattle, WA 98145-5005